BostonGene Highlights Approach to IO Research and Precision Medicine at the 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference

WALTHAM, Mass, June 20, 2023

BostonGene announced today that it will participate in and present at the 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference on June 22 – 23 in Boston, MA. The event brings together academicians, researchers and scientists from research institutes, pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest advancements in the development of ADCs, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy. BostonGene will also exhibit at the conference.

BostonGene session details can be found below:

Elucidation of the Cellular and Molecular Features of the TME Underlying Immune Escape and IO Failure

  • Friday, June 23 | 9:30 AM ET
  • Speaker: Alexander Bagaev, PhD, Vice President, Product Development, BostonGene

Multiple molecular and cellular factors can influence poor patient responses to immunotherapy and IO clinical trial failure.  Although the involvement of these factors is known to impact patient responses, they are often not considered in IO clinical trial enrollment and therapeutic decision-making.  This session will address how BostonGene bridges this gap by providing a comprehensive profile or portrait of a patient’s disease for therapy selection and stratification for IO clinical trials.

To learn more or to schedule a meeting with BostonGene during the event, please contact Maria Proia at


About BostonGene Corporation

BostonGene’s mission is to power healthcare’s transition to personalized medicine using our AI-based molecular and immune profiling to improve the standard of care, accelerate research, and reduce overall cost of cancer care. BostonGene’s tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at

Media Contact:

Erin O’Reilly